Axsome Q1 2026 Revenue Jumps 57% Amid Loss

Axsome posted Q1 2026 revenue $191.2 million, up 57% YoY, but net loss $1.26 per share missed the $0.83 forecast.
AUVELITY drove ~80% of revenue with $153.2 million sales and secured FDA approval for Alzheimer’s disease agitation.
Operating expenses surged, SG&A $185 million and R&D $52.7 million, widening quarterly loss to $64.5 million.
Despite the earnings miss, the stock rose 8% pre‑market to $223.06; peak AUVELITY sales now guided to at least $8 billion.